Spastika, MB - financials and debts

Company age: 2 y. 1 mo.

Update

Spastika - Company finances

EUR
2024
From: 2024-08-20
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 7,017 43,865
Profit before tax -1,391 375
Net profit -1,391 375
Equity 609 983
Liabilities 3,800 877
Non-current assets 0 0
Current assets 4,409 1,860
Total assets 4,409 1,860
Taxes paid
STI taxes 1,216 2,194
Financial indicators
Revenue change y/y - +525.1%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. -31.5% 20.2%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. -228.4% 38.1%
Profit margin Net profit margin. Shows the overall profitability of the company. -19.8% 0.9%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. -19.8% 0.9%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 6.2 0.9
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - -

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Spastika - Social security debts

The company had no debts to Sodra

Spastika - VMI tax arrears

As of 2026-09-02, the amount of overdue STI tax debt of the company Spastika is: 1 €

From To Overdue, €
2026-05-19 2026-09-02 0.65
2026-05-11 2026-05-18 0.85
2026-04-16 2026-05-10 0.65
2026-04-12 2026-04-15 0.85
2026-02-21 2026-04-11 0.65
2026-01-12 2026-01-19 0.65
2025-12-05 2025-12-22 0.3
2025-10-06 2025-10-18 0.3
2025-09-07 2025-09-12 0.3
2025-08-07 2025-08-12 0.3
2025-07-16 2025-07-21 0.3

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Spastika, MB (code 306973420) is a small partnership engaged in medical specialists activities. In 2025, the company generated EUR 43.9K in revenue, a strong increase from EUR 7.0K in the 2024 period, and moved back into profit with net profit of EUR 375 after a EUR 1.4K loss in 2024. The 2025 profit margin was 0.9%, so profitability remained thin despite the much higher turnover. The balance sheet was still very small at year-end 2025, with total assets of EUR 1.9K, equity of EUR 983 and liabilities of EUR 877. The equity ratio stood at 52.9%, indicating a slightly stronger equity position than debt. Returns on equity and assets were strong, but this should be viewed in the context of the very small capital base. Asset turnover was 23.58x, showing that revenue was generated against a limited asset base. Overall, the company’s 2025 performance shows a clear recovery in scale and a return to profitability, although the profit level remained modest.